MedTrace Logo

OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy

NCT06399172 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-05-03

No results posted yet for this study

Summary

The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.

Conditions

  • Locally Advanced Pancreatic Adenocarcinoma

Interventions

DEVICE

OncoSil

Intra-tumoural implantation

Sponsors & Collaborators

  • OncoSil Medical Limited

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2029-05-30
Completion
2029-10-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06399172 on ClinicalTrials.gov